EC HEALTHCARE |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.37 HKD | -2.14% |
|
+3.01% | -21.26% |
| Jan. 31 | EC Healthcare Announces Change of Principal Place of Business in Hong Kong, with Effect from 1 February 2024 | CI |
| Jan. 24 | EC Healthcare's Overall Sales Volume Rises 7% in Q4 2023 | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The company's profit outlook over the next few years is a strong asset.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- The company is one of the best yield companies with high dividend expectations.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- The company sustains low margins.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Sector: Personal Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -21.26% | 212M | - | ||
| +49.64% | 495M | - | ||
| -26.97% | 396M | - | ||
| +0.86% | 272M | - | ||
| -23.87% | 97.99M | - | ||
| -4.95% | 81.73M | - | ||
| -22.13% | 67.74M | - | ||
| -12.41% | 65.03M | - | - | |
| -27.16% | 62.01M | - | - | |
| -.--% | 61.81M | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 2138 Stock
- Ratings EC Healthcare